CSPC Pharmaceutical Group (01093.HK): The Phase I/II clinical study results of SYS6043 (B7-H3 ADC) for the treatment of advanced breast cancer were presented as a rapid oral presentation at the 2026 ESMO Congress.

Zhitong Finance APP News, CSPC Pharmaceutical Group (01093.HK) announced that the results of the Phase I/II clinical study (the study) of SYS6043, a novel B7 homolog 3 (B7-H3)-targeted antibody-drug conjugate (ADC) independently developed by the Group, for patients with advanced breast cancer, were presented on October 26, 2026 in a rapid oral presentation (number: 5RO) at the 2026 European Society for Medical Oncology (ESMO) Annual Congress. The study was presented by Professor Wang Hongxia of Fudan University Shanghai Cancer Center.